share_log

巴克莱银行维持Barinthus Biotherapeutics(BRNS.US)买入评级,维持目标价3美元

Barclays Maintains Barinthus Biotherapeutics(BRNS.US) With Buy Rating, Maintains Target Price $3

Futu News ·  Aug 14 16:32  · Ratings

Barclays analyst Carter Gould maintains $Barinthus Biotherapeutics (BRNS.US)$ with a buy rating, and maintains the target price at $3.

According to TipRanks data, the analyst has a success rate of 56.1% and a total average return of 9.4% over the past year.

AnalystRecentRatingAutoNews_84469122043691_20240814_8640e218dc8203156b97da26aa508ebc79d3f89f_1723725062176123_nn_en

Note:

TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.

Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.

TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment